1.0MedCity Newshttps://medcitynews.comFrank Vinluanhttps://medcitynews.com/author/fvinluan/rich600338<blockquote class="wp-embedded-content" data-secret="eZQbDSj646"><a href="https://medcitynews.com/2026/03/dry-eye-disease-aldeyra-fda-crl-reproxalap-rasp-inflammation-aldx/">Lacking Evidence, FDA Rejects Aldeyra Dry Eye Disease Drug</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://medcitynews.com/2026/03/dry-eye-disease-aldeyra-fda-crl-reproxalap-rasp-inflammation-aldx/embed/#?secret=eZQbDSj646" width="600" height="338" title="“Lacking Evidence, FDA Rejects Aldeyra Dry Eye Disease Drug” — MedCity News" data-secret="eZQbDSj646" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> https://medcitynews.com/wp-content/uploads/sites/7/2021/10/GettyImages-175133840.jpg1024658Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but there is a "lack of substantial evidence" that warrants exploration about the reasons for trial failures to identify the appropriate patients for the eye drop. AbbVie holds an option to collaborate on reproxalab's commercialization.